throbber
Trademark Snap Shot ITU Unit Action
`(Table presents the data on ITU Unit Action)
`
`77309541
`
`0000000
`
`PRINCIPAL
`
`N/A
`
`OVERVIEW
`
`FILING DATE
`
`REG DATE
`
`MARK TYPE
`
`INTL REG DATE
`
`BESCH, JAY C
`
`L.O. ASSIGNED
`
`PUB INFORMATION
`
`08/03/2010
`
`10/07/2008
`
`606-ABANDONED - NO STATEMENT OF USE FILED
`
`SERIAL NUMBER
`
`REG NUMBER
`
`REGISTER
`
`INTL REG #
`
`TM ATTORNEY
`
`RUN DATE
`
`PUB DATE
`
`STATUS
`
`10/22/2007
`
`N/A
`
`TRADEMARK
`
`N/A
`
`108
`
`STATUS DATE
`
`08/02/2010
`
`LITERAL MARK ELEMENT
`
`STABILISE SELECTIVE TREATMENT OF ATHEROSCLEROSIS: DARAPLADIB INIHIBITS LP-PLA2 WITH ANTI-
`INFLAMMATORY AND PLAQUE STABILISING EFFECTS
`
`DATE ABANDONED
`
`08/02/2010
`
`DATE CANCELLED
`
`SECTION 2F
`
`SECTION 8
`
`SECTION 15
`
`RENEWAL FILED
`
`NO
`
`NO
`
`NO
`
`NO
`
`N/A
`
`SECTION 2F IN PART
`
`SECTION 8 IN PART
`
`REPUB 12C
`
`RENEWAL DATE
`
`N/A
`
`NO
`
`NO
`
`N/A
`
`N/A
`
`DATE AMEND REG
`
`1 (a)
`
`1 (b)
`
`44D
`
`44E
`
`66A
`
`NO BASIS
`
`FILED BASIS
`
`FILING BASIS
`
`CURRENT BASIS
`
`AMENDED BASIS
`
`NO
`
`YES
`
`NO
`
`NO
`
`NO
`
`NO
`
`1 (a)
`
`1 (b)
`
`44D
`
`44E
`
`66A
`
`NO BASIS
`
`1 (a)
`
`1 (b)
`
`44D
`
`44E
`
`NO
`
`YES
`
`NO
`
`NO
`
`NO
`
`NO
`
`NO
`
`NO
`
`NO
`
`NO
`
`STANDARD CHARACTER MARK
`
`LITERAL MARK ELEMENT
`
`MARK DRAWING CODE
`
`COLOR DRAWING FLAG
`
`PARTY TYPE
`
`NAME
`
`ADDRESS
`
`MARK DATA
`
`YES
`
`STABILISE SELECTIVE TREATMENT OF ATHEROSCLEROSIS: DARAPLADIB
`INIHIBITS LP-PLA2 WITH ANTI-INFLAMMATORY AND PLAQUE STABILISING
`EFFECTS
`
`4-STANDARD CHARACTER MARK
`
`NO
`
`CURRENT OWNER INFORMATION
`
`20-OWNER AT PUBLICATION
`
`Glaxo Group Limited
`
`Glaxo Wellcome House, Berkeley Avenue
`Greenford, Middlesex,(cid:160)UB60NN
`
`

`

`ENTITY
`
`CITIZENSHIP
`
`INTERNATIONAL CLASS
`
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)DESCRIPTION TEXT
`
`INTERNATIONAL CLASS
`
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)DESCRIPTION TEXT
`
`03-CORPORATION
`
`GB2
`
`GOODS AND SERVICES
`
`016
`
`Printed materials, namely, pamphlets and brochures featuring the treatment and
`prevention of cardiovascular diseases and disorders
`
`042
`
`Medical and scientific research, namely, conducting clinical trials for pharmaceutical
`preparations for the treatment and prevention of cardiovascular diseases and
`disorders
`
`GOODS AND SERVICES CLASSIFICATION
`
`INTERNATIONAL
`CLASS
`
`016
`
`FIRST USE DATE
`
`NONE
`
`INTERNATIONAL
`CLASS
`
`042
`
`FIRST USE DATE
`
`NONE
`
`FIRST USE IN
`COMMERCE
`DATE
`
`FIRST USE IN
`COMMERCE
`DATE
`
`NONE
`
`CLASS STATUS
`
`6-ACTIVE
`
`NONE
`
`CLASS STATUS
`
`6-ACTIVE
`
`CHANGE IN REGISTRATION
`
`DISCLAIMER W/PREDETER TXT
`
`PSEUDO MARK
`
`MISCELLANEOUS INFORMATION/STATEMENTS
`
`NO
`
`"SELECTIVE TREATMENT OF ATHEROSCLEROSIS:DARAPLADIB INIHIBITS LP-
`PLA2 WITH ANTI-INFLAMMATORY AND PLAQUE STABILISING EFFECTS"
`
`STABILISE SELECTIVE TREATMENT OF ATHEROSCLEROSIS: DARAPLADIB
`INIHIBITS LP-PLA TWO WITH ANTI-INFLAMMATORY AND PLAQUE
`STABILISING EFFECTS
`
`DATE
`
`08/02/2010
`
`08/02/2010
`
`05/12/2010
`
`05/03/2010
`
`PROSECUTION HISTORY
`
`ENT CD
`
`ENT TYPE
`
`DESCRIPTION
`
`MAB6
`
`ABN6
`
`TCCA
`
`TCCA
`
`EX2G
`
`O
`
`S
`
`I
`
`I
`
`S
`
`ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
`
`ABANDONMENT - NO USE STATEMENT FILED
`
`TEAS CHANGE OF CORRESPONDENCE RECEIVED
`
`TEAS CHANGE OF CORRESPONDENCE RECEIVED
`
`EXTENSION 2 GRANTED
`
`ENT NUM
`
`037
`
`036
`
`035
`
`034
`
`033
`
`01/30/2010
`
`12/21/2009
`
`01/29/2010
`
`12/21/2009
`
`10/29/2009
`
`07/22/2009
`
`06/29/2009
`
`07/22/2009
`
`06/29/2009
`
`06/02/2009
`
`06/02/2009
`
`12/30/2008
`
`10/07/2008
`
`09/17/2008
`
`EXT2
`
`AITU
`
`EEXT
`
`TCCA
`
`EX1G
`
`EXT1
`
`AITU
`
`EEXT
`
`ARAA
`
`REAP
`
`NOAM
`
`PUBO
`
`NPUB
`
`S
`
`A
`
`I
`
`I
`
`S
`
`S
`
`A
`
`I
`
`I
`
`I
`
`O
`
`A
`
`O
`
`EXTENSION 2 FILED
`
`CASE ASSIGNED TO INTENT TO USE PARALEGAL
`
`TEAS EXTENSION RECEIVED
`
`TEAS CHANGE OF CORRESPONDENCE RECEIVED
`
`EXTENSION 1 GRANTED
`
`EXTENSION 1 FILED
`
`CASE ASSIGNED TO INTENT TO USE PARALEGAL
`
`TEAS EXTENSION RECEIVED
`
`ATTORNEY REVOKED AND/OR APPOINTED
`
`TEAS REVOKE/APPOINT ATTORNEY RECEIVED
`
`NOA MAILED - SOU REQUIRED FROM APPLICANT
`
`PUBLISHED FOR OPPOSITION
`
`NOTICE OF PUBLICATION
`
`032
`
`031
`
`030
`
`029
`
`028
`
`027
`
`026
`
`025
`
`024
`
`023
`
`022
`
`021
`
`020
`
`

`

`09/04/2008
`
`09/04/2008
`
`08/26/2008
`
`08/26/2008
`
`08/26/2008
`
`08/26/2008
`
`08/26/2008
`
`06/26/2008
`
`06/26/2008
`
`06/26/2008
`
`06/06/2008
`
`PREV
`
`ALIE
`
`CNSA
`
`XAEC
`
`GNEN
`
`GNEA
`
`CNEA
`
`GNFN
`
`GNFR
`
`CNFR
`
`TEME
`
`O
`
`A
`
`P
`
`I
`
`O
`
`O
`
`R
`
`O
`
`O
`
`R
`
`I
`
`LAW OFFICE PUBLICATION REVIEW COMPLETED
`
`ASSIGNED TO LIE
`
`APPROVED FOR PUB - PRINCIPAL REGISTER
`
`EXAMINER'S AMENDMENT ENTERED
`
`NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
`
`EXAMINERS AMENDMENT E-MAILED
`
`EXAMINERS AMENDMENT -WRITTEN
`
`NOTIFICATION OF FINAL REFUSAL EMAILED
`
`FINAL REFUSAL E-MAILED
`
`FINAL REFUSAL WRITTEN
`
`TEAS/EMAIL CORRESPONDENCE ENTERED
`
`CORRESPONDENCE RECEIVED IN LAW OFFICE
`
`019
`
`018
`
`017
`
`016
`
`015
`
`014
`
`013
`
`012
`
`011
`
`010
`
`009
`
`008
`
`06/06/2008
`
`06/06/2008
`
`12/07/2007
`
`12/07/2007
`
`12/07/2007
`
`12/03/2007
`
`10/26/2007
`
`10/25/2007
`
`ATTORNEY
`
`CORRESPONDENCE ADDRESS
`
`DOMESTIC REPRESENTATIVE
`
`PARTY TYPE
`
`NAME
`
`ADDRESS
`
`ENTITY
`
`CITIZENSHIP
`
`CRFA
`
`TROA
`
`GNRN
`
`GNRT
`
`CNRT
`
`DOCK
`
`MPMK
`
`NWAP
`
`I
`
`I
`
`O
`
`F
`
`R
`
`D
`
`O
`
`I
`
`TEAS RESPONSE TO OFFICE ACTION RECEIVED
`
`NOTIFICATION OF NON-FINAL ACTION E-MAILED
`
`NON-FINAL ACTION E-MAILED
`
`NON-FINAL ACTION WRITTEN
`
`ASSIGNED TO EXAMINER
`
`NOTICE OF PSEUDO MARK MAILED
`
`NEW APPLICATION ENTERED IN TRAM
`
`CURRENT CORRESPONDENCE INFORMATION
`
`007
`
`006
`
`005
`
`004
`
`003
`
`002
`
`001
`
`Christopher M. Hanes
`
`Christopher M. Hanes
`GlaxoSmithKline
`Five Moore Drive
`LGTM, C.3157.3D
`Research Triangle Park NC 27709
`
`Christopher M. Hanes
`
`PRIOR OWNER INFORMATION
`
`10-ORIGINAL APPLICANT
`
`Glaxo Group Limited
`
`Glaxo Wellcome House, Berkeley Avenue
`Greenford, Middlesex,(cid:160)UB60NN
`
`03-CORPORATION
`
`GB2
`
`

`

`STABILISE SELECTIVE
`
`TREATMENT OF
`
`ATHEROSCLEROSIS:
`
`DARAPLADIB INTPEITS
`
`LP-PLA2 WITH
`
`ANTI-INFLATVIMATORY AND
`PLAQUE STABTLISING EFFECTS
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket